期刊
MOLECULAR & CELLULAR ONCOLOGY
卷 4, 期 4, 页码 -出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/23723556.2017.1338208
关键词
CD49f tumor-initiating cells; chemoresistance; docetaxel; PDX (patient-derived orthoxenografts); triple negative breast cancer (TNBC)
类别
资金
- Spanish Ministry of Economy and Competitivity MINECO
- ISCIII - FEDER funds/European Regional Development Fund (ERDF) - a way to build Europe- [SAF2011-22893, SAF2014-55997, PIE13/00022]
- Susan G Komen Foundation [CCR13262449]
- Generalitat de Catalunya
Taxanes are mainstay treatment of triple negative breast cancer (TNBC) patients but resistance often develops. Using TNBC patient-derived orthoxenografts (PDX) we have recently discovered that a CD49f+ chemoresistant population with tumor-initiating ability is present in sensitive tumors and expands in tumors that have acquired resistance. Importantly, sensitivity to taxanes is recovered after long-term drug interruption. The characterization of this chemoresistant CD49f+ cells provides a unique opportunity to identify novel targets for the treatment of chemoresistant TNBC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据